Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates
Elizabeth C. Smith, Hunter V. Brigman, Jadyn C Anderson, Christopher L. Emery, Tiffany E. Bias, Phillip J. Bergen, Cornelia B. Landersdorfer, Elizabeth B. Hirsch
Abstract
Fosfomycin has been shown to have a wide spectrum of activity against multidrug-resistant Gram-negative bacteria; however, breakpoints have been established only for Escherichia coli or Enterobacterales per the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST), respectively. A lack of additional organism breakpoints limits clinical use of this agent and has prompted extrapolation of these interpretive categories to other organisms like Pseudomonas aeruginosa without supporting evidence.
Topics & Concepts
FosfomycinPseudomonas aeruginosaMicrobiologyBiologyAntimicrobialClinical microbiologyBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyUrinary Tract Infections Management